Capecitabine EP Impurity B
 
		Product Description
CAT No.
				
									ALN-C003003								
				CAS No.
				
									9/5/3094								
				Mol. F.
				
									C9H11FN2O5								
				Mol. Wt.
				
									246.2								
				Stock
				
									Please Inquire								
				
										
							
										Product Overview
						
											
										
							
										Technical Data
						
											
										
							
										Reference
						
											
										
							
										RFQ
						
									
							
							
							Product Overview
			
						
									Chemical Name : 1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoropyrimidine-2,4(1H,3H)-dione (as per EP);
5′-Deoxy-5-fluorouridine (as per USP)								
				
									Smiles : CC1C(C(O)[C@H](N2C(NC(C(F)=C2)=O)=O)O1)O								
				
									Inchi : InChI=1S/C9H12FN3O4/c1-3-5(14)6(15)8(17-3)13-2-4(10)7(11)12-9(13)16/h2-3,5-6,8,14-15H,1H3,(H2,11,12,16)/t3-,5-,6-,8-/m1/s1								
				
									Synonym : Capecitabine USP related compound B ; 5-Fluoro-5′-deoxyuridine								
				
							
							
							Technical Data
			
						
							
							
							Reference
			
						Design of experiments (DoE) - based enhanced quality by design approach to hydrolytic degradation kinetic study of capecitabine by eco-friendly stability indicating UV-visible spectrophotometry
									By Prajapati, Pintu; Patel, Radhika; Patel, Dilan; Shah, ShaileshnFrom American Journal of PharmTech Research (2020), 10(6), 115-133								
				Validated stability indicating HPLC method for estimation of capecitabine
									By Lalitha, K. V.; Raveendra Reddy, J.; Devanna, N. – From International Journal of Pharmaceutical Sciences and Research (2020), 11(11), 5651-5658 								
				RP-HPLC method development and validation for the simultaneous estimation of Irinotecan hydrochloride and Capecitabine in Active Pharmaceutical Ingredients (APIs)
									By Vijaya Jyothi, M.; Bhargav, E.; Keerthana, B.; Varalakshmi, Devi K. – From International Journal of Research in Pharmaceutical Sciences (Madurai, India) (2018), 9(1), 63-67								
				
							
							
							RFQ
			
						
 
                             
                             
                             
                             
                            